NASDAQ:GALTGalectin Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.77 +0.05 (+1.84 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$2.66Now: $2.77▼$2.8050-Day Range$2.61MA: $2.91▼$3.1552-Week Range$1.50Now: $2.77▼$4.50Volume112,900 shsAverage Volume188,791 shsMarket Capitalization$157.97 millionP/E RatioN/ADividend YieldN/ABeta2.53 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Galectin Therapeutics has a potential upside of 134.7% from its current price of $2.77.Amount of Analyst CoverageGalectin Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGalectin Therapeutics has received 328 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGalectin Therapeutics has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentGalectin Therapeutics has received 53.86% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote “Outperform” if you believe GALT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders40.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.40% of the stock of Galectin Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalectin Therapeutics has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GALT Previous Symbol CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone678-620-3186Debt Debt-to-Equity RatioN/A Current Ratio33.35 Quick Ratio33.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book3.64Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-13,290,000.00 Net MarginsN/A Return on Equity-32.09% Return on Assets-29.49%Miscellaneous Employees6 Outstanding Shares57,030,000Market Cap$157.97 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:GALT Rates by TradingView Receive GALT News and Ratings via Email Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions How has Galectin Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GALT stock has increased by 39.2% and is now trading at $2.77. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Galectin Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Galectin Therapeutics. When is Galectin Therapeutics' next earnings date? Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Galectin Therapeutics. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday, May, 11th. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. View Galectin Therapeutics' earnings history. What price target have analysts set for GALT? 2 brokers have issued 1 year price targets for Galectin Therapeutics' shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate Galectin Therapeutics' stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 134.7% from the stock's current price. View analysts' price targets for Galectin Therapeutics. Has Galectin Therapeutics been receiving favorable news coverage? News articles about GALT stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galectin Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Galectin Therapeutics. Who are some of Galectin Therapeutics' key competitors? Some companies that are related to Galectin Therapeutics include Passage Bio (KROS), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), RAPT Therapeutics (RAPT), Aprea Therapeutics (APRE), Radius Health (RDUS), Trillium Therapeutics (TRIL), Basilea Pharmaceutica (BPMUF), Molecular Templates (MTEM), Atreca (BCEL), AnaptysBio (ANAB), Collegium Pharmaceutical (COLL), Ardelyx (ARDX), Legend Biotech (CALT) and Corbus Pharmaceuticals (CRBP). View all competitors. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP) and Verastem (VSTM). Who are Galectin Therapeutics' key executives? Galectin Therapeutics' management team includes the following people: Dr. Harold H. Shlevin, Pres & CEO (Age 69)Mr. Jack W. Callicutt, CFO & Sec. (Age 52)Robert Tritt, Gen. CounselDr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49) What is Galectin Therapeutics' stock symbol? Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT." How do I buy shares of Galectin Therapeutics? Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Galectin Therapeutics' stock price today? One share of GALT stock can currently be purchased for approximately $2.77. How big of a company is Galectin Therapeutics? Galectin Therapeutics has a market capitalization of $157.97 million. The company earns $-13,290,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe. What is Galectin Therapeutics' official website? The official website for Galectin Therapeutics is www.galectintherapeutics.com. How can I contact Galectin Therapeutics? Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
